Table 1 Background characteristics and treatment outcomes of the subjects
Subject | Age/Sex | Baseline ICG features | Number of Half-dose PDT | BCVA (logMAR) | Number of ranibizumab injections | ICG findings at 12-month | Complications | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 3-month | 6-month | 12-month | Polyp | BVN | ||||||
1 | 60/F | 1 polyp | 1 | 0.7 | 0.4 | 0.3 | 0.3 | 3 | Regressed | / | Nil |
2 | 60/F | 1 polyp | 1 | 1.0 | 0.55 | 0.3 | 0.3 | 3 | Regressed | / | Nil |
3 | 77/M | 1 polyp | 1 | 0.3 | 0.3 | 0.2 | 0.2 | 2 | Regressed | / | Nil |
4 | 68/F | 1 polyp | 1 | 0.3 | 0.3 | 0.4 | 0.3 | 4 | Regressed | / | Nil |
5 | 66/M | 1 polyp | 1 | 0.0 | 0.1 | 0.0 | 0.1 | 1 | Regressed | / | Nil |
6 | 71/M | 1 polyp | 1 | 0.1 | 0.1 | 0.1 | 0.1 | 1 | Regressed | / | Nil |
7 | 55/M | 1 polyp | 1 | 1.3 | 0.4 | 0.4 | 0.4 | 2 | Regressed | / | Nil |
8 | 63/M | 2 polyps | 1 | 0.7 | 0.4 | 0.4 | 0.3 | 1 | Regressed | / | Nil |
9 | 52/F | 2 polyps | 2 | 1.0 | 0.7 | 0.7 | 0.6 | 2 | Regressed | / | Nil |
10 | 88/M | 2 polyps | 2 | 0.55 | 0.4 | 0.4 | 0.4 | 2 | Regressed | / | Nil |
11 | 78/M | 2 polyps | 2 | 0.7 | 0.4 | 0.3 | 0.4 | 2 | Regressed | / | Nil |
12 | 75/F | 2 polyps | 2 | 0.55 | 0.3 | 0.4 | 0.3 | 1 | Regressed | / | Nil |
13 | 60/F | 5 polyps | 2 | 1.0 | 0.7 | 1.0 | 1.0 | 7 | Regressed | / | Nil |
14 | 69/M | BVN + 2 polyps | 2 | 0.4 | 0.4 | 0.55 | 0.4 | 2 | Regressed | Persisted | Nil |
15 | 72/F | BVN + 2 polyps | 2 | 0.7 | 0.7 | 0.55 | 0.55 | 2 | Regressed | Persisted | Nil |
16 | 55/F | BVN + 2 polyps | 3 | 1.3 | 1.0 | 1.0 | 1.0 | 5 | Regressed | Persisted | Nil |
17 | 84/F | BVN + 2 polyps | 2 | 0.3 | 0.3 | 0.4 | 0.3 | 1 | Regressed | Persisted | Nil |
18 | 76/M | BVN + 3 polyps | 2 | 0.55 | 0.4 | 0.3 | 0.3 | 2 | Regressed | Persisted | Nil |
19 | 81/M | BVN + 5 polyps | 2 | 0.7 | 0.4 | 0.55 | 0.55 | 2 | Regressed | Persisted | Nil |